Sarah Kavanagh, MPH

  • 1Article
  • 20.3KReads
  • 2022Active
  • 5Collaborators
  • 54Citations

About

Sarah Kavanagh, MPH is affiliated with Kavanagh Statistical Consulting, Apex, North Carolina. Sarah Kavanagh has contributed 1 peer-reviewed article published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders in 2022. Their work focuses on Schizophrenia/Schizoaffective Disorders.

Publications

JCP
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
Original Research

Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ May 11, 2022

This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.